Skip to main content
Premium Trial:

Request an Annual Quote

MicroRNA Start-up Rosetta Genomics Closes $4M Private Equity Round

NEW YORK, March 28 (GenomeWeb News) - Israeli microRNAi-technology start-up Rosetta Genomics has closed a $4-million financing round recently, according to a news report.

 

Rosetta has developed a way to discover microRNA genes, and hopes to begin generating revenue in 2006, according to Globes Online. The current financing round will help the company expand its IP estate and pay for clinical trials on animals for the miniature molecules it has developed.

 

The round, Rosetta's third, was led by Kadima High Tech. Other investors included Israeli drug maker Teva Pharmaceuticals; Leon Recanati; GlenRock Israel; VCON Chairman and CEO Yair Shamir; Agis chairman Moshe Arkin; Uzia Galil; Yoav Chelouche of the Fantine Group; Nathan Hod, former CEO of DSP Communications; Mordechai Segal, cofounder of Libit Signal Processing; Ami Lidor of Lidor Chemicals; Moshe Many, former president of Tel Aviv University, and chairman of Teva's R&D committee; Michael Sela, Israel Prize laureate and former president of the Weizmann Institute of Science; First International Bank of Israel Chairman Joshua Rosensweig; Ehud Arad of the law firm Bach, Arad, Scharf, & Co.; and investor Michael Davis.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.